[Treatment of acute myeloid leukemia with amsacrine and high-dose cytosine arabinoside: a phase II trial].
Ten patients with acute myeloid leukaemia on failure or relapse were treated by Amsacrine and high-dose (12 g/m2) Cytosine Arabinosyl (phase II trial). Four patients achieved complete remission, over six months in one instance. Hematologic toxicity was important but extra-hematologic toxicity was mild. These two drugs could be used as induction or reinforcement treatment in acute myeloid leukaemia.
D000328:Adult; D000609:Aminoacridines / Q000008:administration & dosage* / Q000009:adverse effects; D000677:Amsacrine; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged
D000609:Aminoacridines; D000970:Antineoplastic Agents; D000677:Amsacrine; D003561:Cytarabine
Traitement des leucémies aiguës myéloïdes par amsacrine et hautes doses de cytosine arabinoside: essai phase II.